文献速递冠心病

急性冠脉综合征中指导性选择与强效P2Y12抑制剂治疗比较:15项随机试验61,898例患者的网络荟萃分析

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
PubMed 文献 · Eur Heart J · 2022-01-01

结果显示,指导性选择是唯一与MACE降低相关且不显著增加出血的策略。

要点

  • 指导性选择P2Y12抑制剂与MACE降低相关(IRR 0.80,95%CI 0.65-0.98)。
  • 指导性选择未显著增加所有出血(IRR 1.22,95%CI 0.96-1.55)。
  • 替格瑞洛降低总死亡和心血管死亡,普拉格雷增加大出血。

核心结论

  • 在ACS患者中,与常规选择强效P2Y12抑制剂相比,指导性选择P2Y12抑制剂治疗与最有利的安全性和有效性平衡相关。

主要发现

  • 指导性选择是唯一与MACE降低相关的策略(IRR 0.80,95%CI 0.65-0.98),且不显著增加所有出血(IRR 1.22,95%CI 0.96-1.55)。
  • 指导性选择和普拉格雷与心肌梗死减少相关。
  • 指导性选择、普拉格雷和替格瑞洛与支架血栓减少相关。
  • 替格瑞洛与总死亡和心血管死亡减少相关。
  • 普拉格雷与大出血增加相关,普拉格雷和替格瑞洛与小出血增加相关;卒中发生率在各治疗间无差异。

临床怎么用

  • 在ACS患者中可考虑采用血小板功能或基因检测指导P2Y12抑制剂的选择,以优化安全性和有效性平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the reduction of ischaemic events in patients with acute coronary syndrome (ACS). However, this comes at the expense of increased bleeding. A guided selection of P2Y12 inhibiting therapy has the potential to overcome this limitation. We aimed at evaluating the comparative safety and efficacy of guided vs. routine selection of potent P2Y12 inhibiting therapy in patients with ACS. METHODS AND RESULTS: We performed a network meta-analysis of randomized controlled trials (RCTs) comparing different oral P2Y12 inhibitors currently recommended for the treatment of patients with ACS (clopidogrel, prasugrel, and ticagrelor). RCTs including a guided approach (i.e. platelet function or genetic testing) vs. standard selection of P2Y12 inhibitors among patients with ACS were also included. Incidence rate ratios (IRR) and associated 95% confidence intervals (CIs) were estimated. P-scores were used to estimate hierarchies of efficacy and safety. The primary efficacy endpoint was major adverse cardiovascular events (MACE) and the primary safety endpoint was all bleeding. A total of 61 898 patients from 15 RCTs were included. Clopidogrel was used as reference treatment. A guided approach was the only strategy associated with reduced MACE (IRR: 0.80, 95% CI: 0.65-0.98) without any significant trade-off in all bleeding (IRR: 1.22, 95% CI: 0.96-1.55). A guided approach and prasugrel were associated with reduced myocardial infarction. A guided approach, prasugrel, and ticagrelor were associated with reduced stent thrombosis. Ticagrelor was also associated with reduced total and cardiovascular mortality. Prasugrel was associated with increased major bleeding. Prasugrel and ticagrelor were associated with increased minor bleeding. The incidence of stroke did not differ between treatments. CONCLUSION: In patients with an ACS, compared with routine selection of potent P2Y12 inhibiting therapy (prasugrel or ticagrelor), a guided selection of P2Y12 inhibiting therapy is associated with the most favourable balance between safety and efficacy. These findings support a broader adoption of guided approach for the selection of P2Y12 inhibiting therapy in patients with ACS. STUDY REGISTRATION NUMBER: This study is registered in PROSPERO (CRD42021258603). KEY QUESTION: A guided selection of P2Y12 inhibiting therapy using platelet function or genetic testing improves outcomes among patients undergoing percutaneous coronary intervention. Nevertheless, the comparative safety and efficacy of a guided versus routine selection of potent P2Y12-inhibiting therapy in acute coronary syndrome has not been explored. KEY FINDING: In a comprehensive network meta-analysis including the totality of available evidence and using clopidogrel as treatment reference, a guided approach was the only strategy associated with reduced major adverse cardiovascular events without any significant trade-off in bleeding. Prasugrel and ticagrelor increased bleeding and only ticagrelor reduced mortality. TAKE HOME MESSAGE: A guided selection of P2Y12-inhibiting therapy represents the strategy associated with the most favourable balance between safety and efficacy. These findings support a broader adoption of guided P2Y12 inhibiting therapy in patients with acute coronary syndrome.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Galli, Benenati, Franchi, et al. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Eur Heart J. 2022. PMID: 34918066. doi:10.1093/eurheartj/ehab836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。